前列腺癌筛查随机试验延长随访:发病率与死亡率分析
在PLCO随机试验中,55-74岁男性被分配至每年PSA检测联合直肠指检的干预组或常规护理组;中位随访近17年后,干预组前列腺癌死亡率无显著下降(RR 0.93,95%CI 0.81-1.08;P=0.38),但Gleason 2-6发病率显著增加,Gleason 8-10显著减少。
要点
- 中位随访16.9年,干预组前列腺癌死亡率与常规护理组无显著差异。
- 干预组Gleason 2-6前列腺癌发病率显著升高,Gleason 8-10显著降低。
- 筛查期间干预组无症状病例比例更高(13% vs 27%症状性)。
核心结论
- 经过近17年中位随访,与常规护理相比,每年PSA检测联合直肠指检筛查未显著降低前列腺癌死亡率。
- 干预组Gleason 2-6疾病发病率显著增加,Gleason 8-10疾病显著减少。
研究设计与样本
- 随机对照试验,纳入55-74岁男性,来自10个筛查中心,1993-2001年随机分组。
- 干预组接受6次年度PSA检测和4次年度直肠指检,常规护理组接受常规 care。
- 共38 340例分配至干预组,38 343例至常规护理组;死亡率中位随访16.9年(干预)和16.7年(常规)。
主要发现
- 干预组333例、常规组352例前列腺癌死亡,死亡率分别为5.5和5.9/10 000人年,率比RR 0.93(95%CI 0.81-1.08;P=0.38)。
- 总体前列腺癌发病率RR为1.05(95%CI 1.01-1.09)。
- 按Gleason分级:Gleason 2-6 RR 1.17(95%CI 1.11-1.23),Gleason 7 RR 1.00(95%CI 0.93-1.07),Gleason 8-10 RR 0.89(95%CI 0.80-0.99)。
- 筛查期间,干预组13% vs 常规组27%的病例为症状性诊断;筛查后两组均为18%。
临床怎么用
- 对于55-74岁男性,年度PSA联合直肠指检筛查未显示前列腺癌死亡率获益,临床决策需权衡筛查利弊。
- 筛查更易检出Gleason 2-6低级别前列腺癌,可能带来过度诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine prostate cancer (PCa) incidence and mortality by arm in the randomized Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. PATIENTS AND METHODS: Patients aged 55-74 years at 10 screening centres were randomized between 1993 and 2001 to an intervention or usual care arm. Patients in the intervention arm received six annual prostate-specific antigen (PSA) tests and four annual digital rectal examinations. The patients were followed for PCa incidence and for mortality via active follow-up processes and by linkage to state cancer registries and the National Death Index. For cancers identified through active follow-up, trial abstractors recorded the mode of diagnosis (screen-detected, symptomatic, other). RESULTS: A total of 38 340 patients were randomized to the intervention arm and 38 343 to a usual care arm. The median follow-up for mortality was 16.9 (intervention) and 16.7 years (usual care). There were 333 (intervention) and 352 (usual care) PCa cancer deaths, giving rates (per 10 000 person-years) of 5.5 and 5.9, respectively, and a rate ratio (RR) of 0.93 (95% confidence interval [CI] 0.81-1.08; P = 0.38). The RR for overall PCa incidence was 1.05 (95% CI 1.01-1.09). The RRs by Gleason category were 1.17 (95% CI 1.11-1.23) for Gleason 2-6, 1.00 (95% CI 0.93-1.07) for Gleason 7 and 0.89 (95% CI 0.80-0.99) for Gleason 8-10 disease. By mode of detection, during the trial's screening phase, 13% of intervention arm vs 27% of usual care arm cases were symptomatic; post-screening, these percentages were 18% in each arm. CONCLUSION: After almost 17 years of median follow-up, there was no significant reduction in PCa mortality in the intervention compared with the usual care arm. There was a significant increase in Gleason 2-6 disease and a significant reduction in Gleason 8-10 disease in the intervention compared with the usual care arm.
引用
- Pinsky PF, Miller E, Prorok P, et al. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2018. PMID: 30288918. doi:10.1111/bju.14580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。